{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-244262","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.071193+00:00","generated_at":"2026-05-17T03:02:33.974522+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients","bullets":["Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.","Enrollment exceeded initial target of ~20 patients, total 33 patients enrolled due to patient demand.","Part B includes loading regimen (200mg weekly x4 then every other week) with 36-week dosing; topline data expected mid-2026.","Preliminary PK data shows steady state achieved earlier with loading regimen; signs of clinical activity observed among early patients.","Company plans to advance to pivotal trials pending Part B results."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-244262","json":"https://secwatch.observer/filing/0001193125-25-244262.json","markdown":"https://secwatch.observer/filing/0001193125-25-244262.md","text":"https://secwatch.observer/filing/0001193125-25-244262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525244262/0001193125-25-244262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525244262/d43495d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:02:33.974522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}